Show simple item record

Pneumococcal vaccination coverage among children with sickle cell anemia, sickle cell trait, and normal hemoglobin

dc.contributor.authorReeves, Sarah L.
dc.contributor.authorJary, Hannah K.
dc.contributor.authorGondhi, Jennifer P.
dc.contributor.authorKleyn, Mary
dc.contributor.authorWagner, Abram L.
dc.contributor.authorDombkowski, Kevin J.
dc.date.accessioned2018-09-04T20:09:12Z
dc.date.available2019-12-02T14:55:09Zen
dc.date.issued2018-10
dc.identifier.citationReeves, Sarah L.; Jary, Hannah K.; Gondhi, Jennifer P.; Kleyn, Mary; Wagner, Abram L.; Dombkowski, Kevin J. (2018). "Pneumococcal vaccination coverage among children with sickle cell anemia, sickle cell trait, and normal hemoglobin." Pediatric Blood & Cancer 65(10): n/a-n/a.
dc.identifier.issn1545-5009
dc.identifier.issn1545-5017
dc.identifier.urihttps://hdl.handle.net/2027.42/145560
dc.description.abstractBackgroundChildren with sickle cell anemia and sickle cell trait are at an increased risk of invasive pneumococcal disease compared to children with normal hemoglobin. We assessed and compared pneumococcal vaccination status among these three groups.ProcedureChildren with sickle cell anemia and sickle cell trait were identified using Michigan newborn screening records (1997–2014); each child was matched to four children with normal hemoglobin based on age, Medicaid enrollment (at least 1 year from 2012–2014), race, and census tract. Vaccination records were obtained from the state’s immunization system. Pneumococcal vaccine coverage (PCV7 or PCV13 depending on date of administration) was assessed at milestone ages of 3, 5, 7, and 16 months. The proportion of children with vaccine coverage at each milestone was calculated overall and compared among children with sickle cell anemia, sickle cell trait, and normal hemoglobin using chi‐square tests.ResultsThe study population consisted of 355 children with sickle cell anemia, 17,319 with sickle cell trait, and 70,757 with normal hemoglobin. The proportion of children with age‐appropriate pneumococcal vaccination coverage was low at each milestone and generally decreased over time. Children with sickle cell anemia were more likely to be covered compared to children with sickle cell trait or normal hemoglobin.ConclusionsDespite higher pneumococcal vaccination coverage among children with sickle cell anemia, opportunities for improvement exist among all children. Targeted interventions will benefit from mechanisms to identify children with increased risks such as sickle cell anemia or trait to improve pneumococcal vaccination coverage among these groups.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherinvasive pneumococcal disease
dc.subject.otherMedicaid administrative claims
dc.subject.othersickle cell trait
dc.subject.othersickle cell anemia
dc.subject.otherpneumococcal polysaccharide vaccine
dc.subject.otherpneumococcal conjugate vaccine
dc.titlePneumococcal vaccination coverage among children with sickle cell anemia, sickle cell trait, and normal hemoglobin
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/145560/1/pbc27282.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/145560/2/pbc27282_am.pdf
dc.identifier.doi10.1002/pbc.27282
dc.identifier.sourcePediatric Blood & Cancer
dc.identifier.citedreferenceSpicer JO, Thomas S, Holst A, Baughman W, Farley MM. Socioeconomic and racial disparities of pediatric invasive pneumococcal disease after the introduction of the 7‐valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014; 33: 158 – 164.
dc.identifier.citedreferenceTaylor C, Kavanagh P, Zuckerman B. Sickle cell trait–neglected opportunities in the era of genomic medicine. JAMA. 2014; 311: 1495 – 1496.
dc.identifier.citedreferenceTreadwell MJ, McClough L, Vichinsky E. Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. J Natl Med Assoc. 2006; 98: 704 – 710.
dc.identifier.citedreferenceKorzeniewski SJ, Grigorescu V, Copeland G, et al. Methodological innovations in data gathering: newborn screening linkage with live births records, Michigan, 1/2007–3/2008. Matern Child Health J. 2010; 14: 360 – 364.
dc.identifier.citedreferenceCenters for Medicare and Medicaid Services. Quality rating system measure technical specifications. 2016. Available from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityInitiativesGenInfo/Downloads/2016-QRS-Measure-Technical-Specifications.pdf. Accessed April 5, 2018.
dc.identifier.citedreferenceAmerican Immunization Registry Association. Comparing and communicating vaccination coverage estimates from immunization information systems, the National Immunization Survey, and related assessments. 2017. Available from: http://repository.immregistries.org/files/resources/59a031b40e94f/comparing___communicating_vaccination_coverage_estimates_from_iis__nis__and_related_assessments_-_fi.pdf. Accessed April 5, 2018.
dc.identifier.citedreferenceQ&A About IIS Sentinel Sites. 2016. Available from: https://www.cdc.gov/vaccines/programs/iis/activities/sentinel-sites.html. Accessed April 7, 2018.
dc.identifier.citedreferenceOffice of Disease Prevention and Health Promotion. Healthy people 2020 immunization and infectious diseases. Available from: https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives. Accessed October 3, 2017.
dc.identifier.citedreferenceMcCarthy NL, Irving S, Donahue JG, et al. Vaccination coverage levels among children enrolled in the Vaccine Safety Datalink. Vaccine. 2013; 31: 5822 – 5826.
dc.identifier.citedreferenceMcLaughlin JM, Utt EA, Hill NM, Welch VL, Power E, Sylvester GC. A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: considerations for the routinely‐recommended, pediatric PCV dosing schedule in the United States. Hum Vaccin Immunother. 2016; 12: 206 – 212.
dc.identifier.citedreferenceReeves SL, Braun TM, Dombkowski KJ, Fullerton HJ, Boulton ML, Lisabeth LD. The role of neighborhoods in the receipt of transcranial Doppler screening among children with sickle cell disease. J Pediat Hematol Oncol. 2015; 37: 269 – 273.
dc.identifier.citedreferenceFlannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004; 291: 2197 – 2203.
dc.identifier.citedreferencePoehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006; 295: 1668 – 1674.
dc.identifier.citedreferenceTask Force on Community Preventive Services. Recommendations regarding interventions to improve vaccination coverage in children, adolescents, and adults. Task Force on Community Preventive Services. Am J Prev Med. 2000; 18 ( 1 Suppl ): 92 – 96.
dc.identifier.citedreferenceSaville AW, Beaty B, Dickinson LM, Lockhart S, Kempe A. Novel immunization reminder/recall approaches: rural and urban differences in parent perceptions. Acad Pediatr. 2014; 14: 249 – 255.
dc.identifier.citedreferenceKempe A, Saville A, Dickinson LM, et al. Population‐based versus practice‐based recall for childhood immunizations: a randomized controlled comparative effectiveness trial. Am J public Health. 2013; 103: 1116 – 1123.
dc.identifier.citedreferenceKempe A, Saville AW, Dickinson LM, et al. Collaborative centralized reminder/recall notification to increase immunization rates among young children: a comparative effectiveness trial. JAMA Pediatr. 2015; 169: 365 – 373.
dc.identifier.citedreferenceKempe A, Saville AW, Beaty B, et al. Centralized reminder/recall to increase immunization rates in young children: how much bang for the buck. Acad Pediatr. 2017; 17: 330 – 338.
dc.identifier.citedreferenceBeverung LM, Brousseau D, Hoffmann RG, Yan K, Panepinto JA. Ambulatory quality indicators to prevent infection in sickle cell disease. Am J Hematol. 2014; 89: 256 – 260.
dc.identifier.citedreferenceNero AC, Akuete K, Leasure Reeves S, Dombkowski KJ. Pneumococcal vaccination rates in children with sickle cell disease. J Public Health Manag Pract. 2014; 20: 587 – 590.
dc.identifier.citedreferenceReeves SL, Madden B, Freed GL, Dombkowski KJ. Transcranial Doppler screening among children and adolescents with sickle cell anemia. JAMA Pediatr. 2016; 170: 550 – 556.
dc.identifier.citedreferenceReeves SL, Fullerton HJ, Cohn LM, et al. Missed opportunities for transcranial Doppler screening among children with sickle cell disease. Clin Pediatr (Phila). 2016; 55 ( 12 ): 1093 – 1099.
dc.identifier.citedreferenceRaphael JL, Dietrich CL, Whitmire D, Mahoney DH, Mueller BU, Giardino AP. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer. 2009; 52: 263 – 267.
dc.identifier.citedreferenceBoulet SL, Yanni EA, Creary MS, Olney RS. Health status and healthcare use in a national sample of children with sickle cell disease. Am J Prev Med; 38: S528 – S535.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Sickle Cell Disease, Data and Statistics. https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 2, 2018.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Pneumococcal disease: surveillance and reporting. 2016. Available from: https://www.cdc.gov/pneumococcal/surveillance.html. Accessed October 7, 2017.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children — use of 13‐valent pneumococcal conjugate vaccine and 23‐valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59 ( RR‐11 ): 1 – 19.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Immunization. 2017. Available from: https://www.cdc.gov/nchs/fastats/immunize.htm. Accessed August 30, 2017.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Vaccines and preventable disease. 2016. Available from: https://www.cdc.gov/vaccines/vpd/pneumo/index.html. Accessed October 07, 2017.
dc.identifier.citedreferenceBlack SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001; 20: 1105 – 1107.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS): Invasive Pneumococcal Disease (IPD) (Streptococcus pneumoniae) 2017 Case Definition. 2017. Available from: https://wwwn.cdc.gov/nndss/conditions/invasive-pneumococcal-disease/case-definition/2017/. Accessed October07, 2017.
dc.identifier.citedreferenceYildirim I, Shea KM, Little BA, Silverio AL, Pelton SI. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease. Pediatrics. 2015; 135: 495 – 503.
dc.identifier.citedreferenceNuorti JP, Whitney CG, Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children ‐ use of 13‐valent pneumococcal conjugate vaccine and 23‐valent pneumococcal polysaccharide vaccine ‐ recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59 ( RR‐11 ): 1 – 18.
dc.identifier.citedreferenceCober MP, Phelps SJ. Penicillin prophylaxis in children with sickle cell disease. J Pediatr Pharmacol Ther. 2010; 15: 152 – 159.
dc.identifier.citedreferenceMartin OO, Moquist KL, Hennessy JM, Nelson SC. Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era. Pediatr Blood Cancer. 2018; 65.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Sickle cell disease (SCD): 5 tips to help prevent infections. 2016. Available from: https://www.cdc.gov/ncbddd/sicklecell/healthyliving-prevent-infection.html. Accessed October3, 2017.
dc.identifier.citedreferenceNational Heart Lung and Blood Institute. Evidence based management of sickle cell disease. 2014. Available from: https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%20020816_0.pdf. Accessed June 2, 2018.
dc.identifier.citedreferenceHampton ML, Anderson J, Lavizzo BS, Bergmen AB. Sickle cell “nondisease.” A potentially serious public health problem. Am J Dis Child. 1974; 128: 58 – 61.
dc.identifier.citedreferencePerrine RP, Brown MJ, Clegg JB, Weatherall DJ, May A. Benign sickle‐cell anaemia. Lancet. 1972; 2: 1163 – 1167.
dc.identifier.citedreferenceKhan U, Kleess L, Yeh J, Berko C, Kuehl S. Sickle cell trait: not as benign as once thought. J community Hospital Intern Med Perspect. 2014; 4: 25418.
dc.identifier.citedreferenceGoldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg MH. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. Am J Hematol. 2012; 87: 340 – 346.
dc.identifier.citedreferencePoehling KA, Light LS, Rhodes M, et al. Sickle cell trait, hemoglobin C trait, and invasive pneumococcal disease. Epidemiology. 2010; 21: 340 – 346.
dc.identifier.citedreferenceHarrison SE, Walcott CM, Warner TD. Knowledge and awareness of sickle cell trait among young African American adults. West J Nurs Res. 2017; 39: 1222 – 1239.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.